To explore the impact of SH3BP5 expression on immunotherapy, response rates to therapies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) were assessed in patients with DLBCL exhibiting high and low SH3BP5 expression using a subclass mapping approach. This evidence concerns the gene SH3BP5 and diffuse large B-cell lymphoma.